CRNA secures NOK 620 million funding, touts circVec gains
Circio Holding ASA said circVec delivered up to 60x improved gene expression in vivo, with next-gen targeting 200x, alongside NOK 620 million in funding to support R&D expansion and collaborations.
Major advances in circVec technology led to up to 60x improved gene expression in vivo, with next-gen targeting 200x.
Secured NOK 620 million in funding, supporting R&D expansion and collaborations, and reducing financial risk through 2030.Based on Circio Holding ASA [CRNA] Q2 2026 Audio Transcript…